Home / Business and Economy / Chemed Earnings Soar Past Estimates
Chemed Earnings Soar Past Estimates
29 Jul
Summary
- Chemed's quarterly earnings exceeded estimates by 9.19%.
- Revenues for the quarter also surpassed expectations.
- The company's shares have gained 19% year-to-date.
Chemed, an operator of Roto-Rooter and Vitas Healthcare, announced its second-quarter earnings, significantly outperforming market expectations. The company reported earnings of $6.06 per share, beating the Zacks Consensus Estimate of $5.55 by a notable 9.19%.
This earnings beat follows a strong performance in the previous quarter, where Chemed delivered an earnings surprise of 9.28%. Overall, the company has surpassed consensus EPS estimates in two of the last four quarters.
In addition to strong earnings, Chemed's revenues for the quarter ended June 2026 reached $673.25 million, exceeding the Zacks Consensus Estimate by 1.86%. This marks a significant increase from the $618.8 million reported in the same quarter last year.
Chemed shares have performed exceptionally well, gaining approximately 19% since the beginning of 2026, substantially outperforming the S&P 500's 8.3% gain. The company currently holds a Zacks Rank #3 (Hold), indicating expected in-line market performance.
Looking ahead, the consensus EPS estimate for the coming quarter is $6.01, with revenues projected at $669.51 million. For the current fiscal year, the company anticipates earnings of $24.42 per share on revenues of $2.69 billion.
